Chief Medical Officer DAVA Oncology
Oncology
Dr. John R. Eckardt, MD
|
|
Give Review
John R. Eckardt, MD works in the field of Oncology. He graduated from Saint Louis University School of Medicine. Saint Louis University School of Medicine is ranked 67/57 in Research/PrimaryCare. John R. Eckardt is a published MD as well. He has 69 publications published. The latest was: A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
Publications
- A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies.
- Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer.
- Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
- Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with ex...
- A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
- Emerging role of weekly topotecan in recurrent small cell lung cancer.
- Second-line treatment of small-cell lung cancer. The case for systemic chemotherapy.
- Topotecan in relapsed small-cell lung cancer: can good things come in small packages?
- The role of adjuvant radiotherapy in the treatment of resectable desmoid tumors.
- Hemangiopericytoma of bone.
- Challenging the platinum combinations in the chemotherapy of NSCLC.
- Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.
- [Preoperative chemotherapy in treatment of soft tissue sarcoma].
- Surgical treatment and chemotherapy for pulmonary metastases from osteosarcoma.
- Comparison of engraftment and acute GVHD in patients undergoing cryopreserved or fresh allogeneic BMT.
- Antitumor activity of docetaxel.
- New approaches to the treatment of advanced breast cancer.
- New anticancer agents.
- Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).
- A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.
- Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer.
- Synovial sarcoma. A study of intensive chemotherapy in 14 patients with localized disease.
- Development of docetaxel in advanced non-small-cell lung cancer.
- Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarc...
- Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study.
- Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.
- Heat shock proteins and drug resistance.
- Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial.
- New drugs in clinical development in the United States.
- Options for first- and second-line therapy in small cell lung cancer--a workshop discussion.
- Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro.
- Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.
- Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial.
- Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.
- Recent advances with topotecan in the treatment of lung cancer.
- Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.
- Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.
- Single-agent chemotherapy for non-small cell lung cancer.
- A phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon.
- A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema.
- Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.
- Preclinical and phase I trials of topoisomerase I inhibitors.
- A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies.
- Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine pl...
- Feasibility of oral topotecan in previously untreated patients with small-cell lung cancer ineligible for standard therapy.
- New anticancer agents in clinical development.
- Feasibility of oral topotecan plus intravenous paclitaxel in advanced non-small-cell lung cancer.
- Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors.
- A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
- Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
- Phase I study with the DNA sequence-specific agent adozelesin.
- A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium.
- A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea.
- A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion.
- A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors.
- Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors.
- A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer.
- A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors.
- Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
- Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma.
- Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.
- Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.
- Phase I and pharmacokinetic trial of weekly CPT-11.
- Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
- Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
- Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
- A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
- A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Schools
Saint Louis University School Of Medicine
St Johns Mercy Med Center
MedOnc Hematology University Of Tex Health Science
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas Health Science Center -
Saint Louis University School of Medicine